Key Points
- Brent Sabatini, Vir's chief accounting officer, sold 7,711 shares on March 23 at an average price of $9.12 for roughly $70,324, cutting his ownership by 11.08% to 61,902 shares.
- Vir reported Q4 EPS of ($0.31) beating estimates and revenue of $64.07M (up 417.8% YoY), yet remains unprofitable; several analysts have raised price targets (Needham, Barclays, HC Wainwright) and the consensus target is about $20.44 with a "Moderate Buy" rating.
Vir Biotechnology, Inc. (NASDAQ:VIR - Get Free Report) CAO Brent Sabatini sold 7,711 shares of the company's stock in a transaction that occurred on Monday, March 23rd. The stock was sold at an average price of $9.12, for a total value of $70,324.32. Following the transaction, the chief accounting officer directly owned 61,902 shares in the company, valued at approximately $564,546.24. This trade represents a 11.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website.
Brent Sabatini also recently made the following trade(s):
- On Tuesday, February 24th, Brent Sabatini sold 1,430 shares of Vir Biotechnology stock. The shares were sold at an average price of $9.53, for a total value of $13,627.90.
- On Monday, February 23rd, Brent Sabatini sold 1,829 shares of Vir Biotechnology stock. The stock was sold at an average price of $7.45, for a total value of $13,626.05.
- On Friday, February 13th, Brent Sabatini sold 1,530 shares of Vir Biotechnology stock. The shares were sold at an average price of $7.79, for a total transaction of $11,918.70.
Vir Biotechnology Trading Up 4.9%
Shares of VIR stock opened at $8.99 on Thursday. The firm has a fifty day simple moving average of $8.20 and a two-hundred day simple moving average of $6.66. Vir Biotechnology, Inc. has a 12 month low of $4.16 and a 12 month high of $10.94. The firm has a market capitalization of $1.25 billion, a PE ratio of -2.84 and a beta of 1.65.
Vir Biotechnology (NASDAQ:VIR - Get Free Report) last issued its quarterly earnings data on Monday, February 23rd. The company reported ($0.31) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.42) by $0.11. Vir Biotechnology had a negative net margin of 638.88% and a negative return on equity of 49.31%. The firm had revenue of $64.07 million during the quarter, compared to analysts' expectations of $19.91 million. During the same period last year, the company earned ($0.76) earnings per share. The business's revenue was up 417.8% on a year-over-year basis. On average, equities analysts predict that Vir Biotechnology, Inc. will post -3.92 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several equities research analysts recently issued reports on the company. Needham & Company LLC upped their price target on Vir Biotechnology from $14.00 to $18.00 and gave the stock a "buy" rating in a report on Tuesday, February 24th. Wall Street Zen upgraded shares of Vir Biotechnology from a "sell" rating to a "hold" rating in a research note on Saturday, February 28th. Barclays raised their price target on shares of Vir Biotechnology from $26.00 to $30.00 and gave the company an "overweight" rating in a research report on Tuesday, February 24th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Vir Biotechnology in a research report on Monday, December 22nd. Finally, HC Wainwright lifted their target price on shares of Vir Biotechnology from $15.00 to $20.00 and gave the stock a "buy" rating in a research report on Wednesday, March 4th. One research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $20.44.
View Our Latest Stock Analysis on VIR
Hedge Funds Weigh In On Vir Biotechnology
Institutional investors have recently bought and sold shares of the company. Mirae Asset Global Investments Co. Ltd. grew its holdings in Vir Biotechnology by 25.9% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,761 shares of the company's stock valued at $41,000 after purchasing an additional 1,390 shares during the period. CWM LLC grew its stake in shares of Vir Biotechnology by 23.0% during the 4th quarter. CWM LLC now owns 8,804 shares of the company's stock worth $53,000 after acquiring an additional 1,646 shares during the period. ProShare Advisors LLC increased its holdings in Vir Biotechnology by 7.8% in the 4th quarter. ProShare Advisors LLC now owns 23,525 shares of the company's stock worth $142,000 after acquiring an additional 1,705 shares during the last quarter. Clarius Group LLC raised its stake in Vir Biotechnology by 0.3% in the 3rd quarter. Clarius Group LLC now owns 619,312 shares of the company's stock valued at $3,536,000 after acquiring an additional 1,777 shares during the period. Finally, Rhumbline Advisers lifted its holdings in Vir Biotechnology by 1.0% during the second quarter. Rhumbline Advisers now owns 228,949 shares of the company's stock valued at $1,154,000 after purchasing an additional 2,300 shares during the last quarter. Hedge funds and other institutional investors own 65.32% of the company's stock.
Vir Biotechnology Company Profile
(
Get Free Report)
Vir Biotechnology, Inc is a clinical‐stage immunology company dedicated to developing therapies that prevent and treat serious infectious diseases. The company leverages a suite of proprietary technology platforms—ranging from antibody isolation and screening tools to cell‐based assays and bioinformatics—to identify and advance antiviral and antibacterial candidates. Its scientific approach centers on harnessing the human immune system through monoclonal antibodies and immunomodulatory agents.
The company's pipeline includes product candidates targeting influenza A, COVID‐19, HIV, hepatitis B, and tuberculosis.
Featured Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
